Decreasing formalin concentration improves quality of DNA extracted from formalin-fixed paraffin-embedded tissue specimens without compromising tissue morphology or immunohistochemical staining.


Journal

Journal of clinical pathology
ISSN: 1472-4146
Titre abrégé: J Clin Pathol
Pays: England
ID NLM: 0376601

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 10 12 2019
revised: 16 12 2019
accepted: 17 12 2019
pubmed: 11 1 2020
medline: 4 8 2020
entrez: 11 1 2020
Statut: ppublish

Résumé

Genomic technologies are increasingly used clinically for both diagnosis and guiding cancer therapy. However, formalin fixation can compromise DNA quality. This study aimed to optimise tissue fixation using normal colon, liver and uterus (n=8 each) by varying neutral buffered formalin (NBF) concentration (1%-5% w/v) and fixation time (24-48 hours). Fixation using 4% NBF improved DNA quality (assessed by qPCR) compared with routine (4% unbuffered formal saline-fixed) specimens (p<0.01). Further improvements were achieved by reducing NBF concentration (p<0.00001), whereas fixation time had no effect (p=0.110). No adverse effects were detected by histopathological or QuPath morphometric analysis. Immunohistochemistry for multicytokeratin and α-smooth muscle actin revealed no changes in staining specificity or intensity in any tissue other than on liver multicytokeratin staining intensity, where the effect of fixation time was more significant (p=0.0004) than NBF concentration (p=0.048). Thus, reducing NBF concentration can maximise DNA quality without compromising tissue morphology or standard histopathological analyses.

Identifiants

pubmed: 31919142
pii: jclinpath-2019-206368
doi: 10.1136/jclinpath-2019-206368
doi:

Substances chimiques

Fixatives 0
Formaldehyde 1HG84L3525
DNA 9007-49-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

514-518

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Michele Cummings (M)

Women's Health Research Group, Pathology & Data Analytics, Leeds Institute of Medical Research at St. James's, University of Leeds, Wellcome Trust Brenner Building, Leeds, UK.

Henry King (H)

Women's Health Research Group, Pathology & Data Analytics, Leeds Institute of Medical Research at St. James's, University of Leeds, Wellcome Trust Brenner Building, Leeds, UK.

James Hurst (J)

Women's Health Research Group, Pathology & Data Analytics, Leeds Institute of Medical Research at St. James's, University of Leeds, Wellcome Trust Brenner Building, Leeds, UK.

Georgette Tanner (G)

Women's Health Research Group, Pathology & Data Analytics, Leeds Institute of Medical Research at St. James's, University of Leeds, Wellcome Trust Brenner Building, Leeds, UK.

Leah Khazin (L)

Women's Health Research Group, Pathology & Data Analytics, Leeds Institute of Medical Research at St. James's, University of Leeds, Wellcome Trust Brenner Building, Leeds, UK.

Phillip Thompson (P)

Department of Histopathology, St. James's University Hospital, Leeds, UK.

Allan Gray (A)

Department of Histopathology, St. James's University Hospital, Leeds, UK.

Narinder Gahir (N)

Women's Health Research Group, Pathology & Data Analytics, Leeds Institute of Medical Research at St. James's, University of Leeds, Wellcome Trust Brenner Building, Leeds, UK.

Caroline Cartlidge (C)

Women's Health Research Group, Pathology & Data Analytics, Leeds Institute of Medical Research at St. James's, University of Leeds, Wellcome Trust Brenner Building, Leeds, UK.

Zara Farooq (Z)

Women's Health Research Group, Pathology & Data Analytics, Leeds Institute of Medical Research at St. James's, University of Leeds, Wellcome Trust Brenner Building, Leeds, UK.

Keyura Raveendran (K)

Women's Health Research Group, Pathology & Data Analytics, Leeds Institute of Medical Research at St. James's, University of Leeds, Wellcome Trust Brenner Building, Leeds, UK.

Katie Allen (K)

Women's Health Research Group, Pathology & Data Analytics, Leeds Institute of Medical Research at St. James's, University of Leeds, Wellcome Trust Brenner Building, Leeds, UK.
Department of Histopathology, St. James's University Hospital, Leeds, UK.

Olorunda Rotimi (O)

Department of Histopathology, St. James's University Hospital, Leeds, UK.

Nicolas M Orsi (NM)

Women's Health Research Group, Pathology & Data Analytics, Leeds Institute of Medical Research at St. James's, University of Leeds, Wellcome Trust Brenner Building, Leeds, UK n.m.orsi@leeds.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH